A review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.
André P. Fay, MD
Advertisement
Articles by André P. Fay, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5